Cagrilintide for Body Composition: A Lifter's Look

Most of the body-composition conversation in the peptide world has been dominated by GLP-1 drugs — semaglutide, then tirzepatide, now triple agonists. Cagrilintide is a different lever entirely. It's a long-acting amylin analog, and it's interesting to lifters for a specific reason: amylin works on appetite and satiety through a pathway that may preserve lean mass better than aggressive GLP-1 mono-therapy. Whether that promise holds up is still an open question, but it's worth understanding why cagrilintide keeps coming up.

This is a clear-eyed look at what cagrilintide is, what the human data actually shows, and whether a strength-focused person should care.

What amylin does, and why it's not just another GLP-1

Amylin is a hormone co-secreted with insulin by the pancreatic beta cells. After you eat, insulin and amylin go out together. While insulin manages blood glucose, amylin handles the other side of the meal: it slows gastric emptying, suppresses glucagon, and signals satiety to the brain. It's a natural "you've eaten enough" signal.

Native amylin is useless as a drug — it aggregates and has a half-life measured in minutes. Cagrilintide is the engineered fix: a modified, acylated amylin analog with a half-life long enough for once-weekly dosing, similar to how semaglutide re-engineered GLP-1 for weekly use.

The key distinction from GLP-1 drugs is the receptor target. GLP-1 agonists hit GLP-1 receptors; cagrilintide hits amylin and calcitonin receptors. That's a different appetite-suppression pathway, which is exactly why researchers got interested in combining the two — you can stack two non-overlapping satiety mechanisms for a larger effect than either alone.

The data so far

Cagrilintide's most-cited evidence comes from two directions: cagrilintide on its own, and cagrilintide combined with semaglutide (the combination is known in trials as CagriSema).

As a standalone, a Phase 2 trial of cagrilintide monotherapy at various doses produced meaningful weight loss over 26 weeks in people with obesity, with the higher doses outperforming a semaglutide comparator arm in that study. That was the signal that amylin agonism wasn't just an add-on — it had standalone power.

As CagriSema (cagrilintide + semaglutide together), the combination has driven some of the largest weight-loss numbers reported for an injectable, in the same league as tirzepatide. The two-mechanism stack appears to be additive.

What we don't have is the data lifters most want: detailed body-composition breakdowns showing how much of the weight lost is fat versus lean mass, measured with DEXA, in trained people doing resistance work. The trials were designed around total weight loss in people with obesity, not lean-mass retention in athletes. So the "muscle-sparing" idea is a hypothesis based on mechanism, not a proven outcome.

The muscle-sparing argument — and its limits

Here's the reasoning lifters find appealing. Aggressive appetite suppression from any drug creates a large calorie deficit, and large deficits cost lean mass unless protein and training are dialed in. The fear with GLP-1 mono-therapy is that the deficit gets so deep, so fast, that muscle goes along with the fat.

The amylin angle is that amylin's satiety signal may be more "physiological" — it mimics a natural post-meal fullness rather than the more dramatic gut-slowing of high-dose GLP-1. The hope is that this produces a more moderate, sustainable deficit that's easier to support with adequate protein, leaving more muscle intact.

That's a reasonable mechanistic story. But "may be gentler" is not "spares muscle," and the deficit math doesn't care which drug created it. Any tool that drops your appetite hard enough to lose fat fast will cost lean mass if you under-eat protein and stop training. No injectable changes that. If you're going to use cagrilintide or CagriSema for body recomposition, the lean-mass outcome will be decided by your protein intake and your resistance training — not by the peptide's receptor profile. This is the same lesson we keep returning to with GLP-1 drugs in our piece on keeping lean mass on a peptide stack.

How cagrilintide compares to the alternatives

The pattern is consistent across the whole category: the appetite-suppression numbers are impressive and the trained-population body-composition data is thin to nonexistent. Cagrilintide isn't uniquely under-studied here — the entire incretin/amylin space has the same gap. Our comparison of tirzepatide vs semaglutide for body composition covers the same caveat from the GLP-1 side.

Practical considerations for lifters

If you're considering cagrilintide, a few realities matter more than the mechanism:

• Sourcing and identity. Cagrilintide is newer and less common in the research-chemical market than semaglutide. That means more identity uncertainty and fewer COAs to compare against. Vet the vendor hard — see our vendor due diligence checklist.
• Nausea and GI effects. Like GLP-1 drugs, amylin agonists slow gastric emptying, so nausea, fullness, and reduced food intake are expected, especially early. For a lifter trying to hit a protein target, that's a real obstacle — you may be fighting the drug to eat enough.
• Protein becomes non-negotiable. Because the whole point is suppressed appetite, you have to be deliberate about protein. Liquid protein and smaller, frequent meals tend to be the workaround.
• It's not anabolic. Cagrilintide doesn't build muscle. It's a fat-loss tool whose best lifter use is during a cut, paired with enough resistance training and protein to hold onto what you've built. If your goal is mass or recovery, you're looking at the wrong category — see the GH secretagogues or IGF-1 LR3 pillars instead.

Titration: the part people get wrong

If there's one practical mistake that defines this whole drug class, it's starting too high. Amylin and GLP-1 agonists are dose-titrated for a reason — the GI side effects are dose-dependent and front-loaded, and jumping to a high dose to "get results faster" usually just buys you a week of nausea and a few skipped training sessions.

The trial protocols for cagrilintide and CagriSema used gradual dose escalation over weeks, letting the gut adapt before stepping up. Replicating that patience matters more for a lifter than for the average user, because your goal isn't just to lose weight — it's to keep eating enough protein and keep training hard throughout. A slow titration protects both. The fastest route to losing muscle on this class of drug is a too-aggressive dose that wrecks your appetite and your gym attendance in the same week.

What to monitor

If you use cagrilintide, a few things are worth tracking beyond the scale:

• Protein intake, daily. This is the single biggest determinant of whether the weight you lose is fat or muscle. Suppressed appetite makes hitting your target hard — track it, don't estimate it.
• Training performance. Strength and gym output are a real-time readout of whether you're under-recovering. If your numbers are falling fast, your deficit is too steep or your protein is too low.
• Blood glucose, if you have any metabolic risk. Amylin affects glucagon and gastric emptying; the interaction with other glucose-lowering tools matters. This is doubly true if you're combining it with anything in the GLP-1 family.
• Hydration and electrolytes. Reduced food intake means reduced incidental water and electrolytes — a common and avoidable cause of feeling terrible on these drugs.

None of this is exotic, but it's the difference between using cagrilintide as a controlled cutting tool and using it as a blunt instrument that takes muscle with the fat.

The bottom line

Cagrilintide is one of the more genuinely interesting newer peptides for body composition, because amylin agonism is a real, distinct satiety mechanism with standalone Phase 2 efficacy — not just hype. The CagriSema combination data is impressive. But the specific thing lifters want — proven lean-mass preservation during a cut, measured in trained people — doesn't exist yet. What we have is a plausible mechanism and strong total-weight-loss numbers.

Treat cagrilintide as a powerful appetite-suppression tool, not a body-recomposition shortcut. If you use it, the muscle you keep will come from protein and training, exactly as it would with any other drug in this class. And given how new it is on the research-chemical side, sourcing caution matters more here than with the established peptides.

Related reading

• Tirzepatide vs semaglutide for body composition
• Keeping lean mass on a peptide stack
• Vendor due diligence checklist
• Cutting with peptides: what works